AIUM: TRUS or MRI for prostate diagnosis?
ORLANDO, FL – Although multiparametric MRI (mpMRI) may be widely considered...Read more on AuntMinnie.comRelated Reading: Prostate cancer incidence, mortality decline worldwide Standardized accreditation is key for prostate MRI Faster MRI protocol avoids unneeded prostate biopsies MRI-based risk model improves prostate cancer detection MR/TRUS fusion biopsy targets high-risk prostate cancer
The name of Stirling Bryan was incorrectly captured in the original manuscript.
Authors: Rodriguez S, Sparks AD, Zhou H, Amdu RL, Lin J Abstract INTRODUCTION: To evaluate the impact of prostate cancer screening guidelines on different racial and ethnic populations. MATERIALS AND METHODS: Data was collected from the 2005-2015 Surveillance, Epidemiology, and End Results (SEER) program. Incidence of prostate cancer diagnosis was categorized and analyzed by stage, race/ethnicity, and age group. Appropriate univariate and multivariable statistical analysis was performed. RESULTS: The odds of being diagnosed with regional-stage prostate cancer in 2013-2015 were 1.3 times higher for black men...
Authors: Morgans AK, Szymaniak BM Abstract The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing. PMID: 31629435 [PubMed - in process]
Authors: Hyatt C, Russo J, McDougall C Abstract Germline genetic testing for prostate cancer is helping to inform risk stratification and staging of prostate cancer and also screening for men with family history of prostate cancer. Genetic counseling is an important piece of germline genetic testing; however there can be limitations of access to genetic counselors and other genetic professionals. It is important to integrate genetic counseling with urology and primary care practices. PMID: 31629434 [PubMed - in process]
Authors: Concepcion RS Abstract In an attempt to better understand how community urology practices would begin to incorporate hereditary testing in prostate cancer patients, we developed an eight-question on line survey to identify current testing patterns, utilization of genetic counseling and barriers that practices face. Fifty-two large community urology practices participated. A total of 32/52 (63%) of the responders were already offering testing to select patients. The big hurdles practices were concerned when initiating testing were fear of medical/legal liability (22%), concerns over reimbursement and out of...
Authors: Helfand BT, Xu J Abstract Based upon an evidence-based review of recently published manuscripts including our own studies, we first review germline variants that are significantly associated with prostate cancer aggressiveness and progression. We then discuss the clinical implication of germline variants in predicting grade reclassification of prostate cancer patients undergoing active surveillance. Finally, based on currently available evidence, we propose a working recommendation of germline testing and corresponding clinical management for localized prostate cancer patients, including those undergoing a...
Authors: Polascik TJ, Orabi H Abstract Prostate cancer screening remains controversial in the medical field. While screening men above 50 years can impose overdiagnosis and overtreatment, targeted screening of males with pathologic variants of genetic mutations is evolving and viewed as sensible. Identifying such patients requires genetic testing in males having family history of prostate cancer or certain ethnicity. Such strategies will likely occur as routine practice once favorable results of ongoing studies assessing genetic predisposition are released. PMID: 31629431 [PubMed - in process]
Authors: Giri VN Abstract Germline testing for inherited prostate cancer is revolutionizing prostate cancer treatment for advanced and metastatic disease and is beginning to inform management for early-stage disease as well as prostate cancer screening discussions. Increasingly, non-genetic providers are performing genetic testing in their practices, necessitating focused efforts to address genetic education and working knowledge of genetic testing for responsible delivery of testing to men with or at risk for prostate cancer. PMID: 31629430 [PubMed - in process]
Authors: Woodson AH Abstract Genetic counseling for men with prostate cancer has unique considerations. While the main components of the genetic counseling session are similar to other indications, specific attention to penetrance differences among hereditary cancer genes for male versus female-related cancer risks and future cancer surveillance among prostate cancer patients should be included. Limitations in discerning the contribution to prostate cancer and risks to relatives dependent on specific gene mutations, or absence of identifiable genetic cause, must be reviewed. PMID: 31629428 [PubMed - in process]
Authors: Pilarski R Abstract With the advent of next-generation sequencing technologies, genetic testing of prostate cancer patients is now typically done using multi-gene panels. These vary from targeted disease-specific panels to comprehensive (pan-cancer) panels, with advantages and disadvantages for each. This paper reviews a number of issues raised in choosing the best panels and labs to use, and issues presented by the increasing availability of direct-to-consumer testing. PMID: 31629427 [PubMed - in process]